ASP Isotopes at emerging growth conference: push to commercialize key materials

ASP Isotopes Inc. (ASPI) presented its strategy to commercialize various development projects at the Emerging Growth Conference on 20 August 2026. CEO Paul Mann noted the company is approaching a significant transition, but acknowledged execution risks, supply shortages, and market volatility across helium, isotope, and nuclear fuel businesses.

ASPI's stock has seen significant volatility, currently trading at $3.91, down approximately 73% from its 52-week high of $14.49. With a beta of 3.62, the stock is more volatile than the broader market. The company aims to bring most of its divisions into commercial production within six months, with revenue and free cash flow expected to follow.

Management highlighted the challenging helium and some medical isotope supply situations, where shortages have driven prices higher and left customers concerned about availability. Several units are progressing toward commercial production, including helium and LNG in South Africa, silicon-28, carbon-14, and ytterbium-176. ASP Isotopes said nearly 50% of global helium supply is unavailable, with spot prices exceeding $2,000 per MCF.

Phase 2 of the South African helium and LNG project is fully funded with around $750 million in committed capital.

PET Labs, focusing on radioisotopes and radiopharmaceuticals, posted over 50% revenue growth in the first half of 2024 and expects revenue to double in 2026 compared to 2025. Renergen, responsible for helium and energy production, manages the South African helium and LNG asset. Quantum Leap Energy, preparing as a separate company focused on HALEU, lithium-6, lithium-7, and LEU-plus nuclear fuels, is expected to complete its spinoff by the end of 2024.

Mann emphasized the importance of the next six months, as the company shifts from development to production, aiming to generate revenues and free cash flow before expanding capacity further.